Themis Medicare update on litigation related to USFDA directives

Themis Medicare had received a letter dated 11 July, 2018 from the Food and Drug Administration (FDA) authorities directing, inter alia, not to manufacture a key product till deciding of the matter. The Company, being aggrieved by the developments, had filed a Writ Petition in the Hon'ble Delhi High Court in this connection and the same was admitted by the Hon'ble Delhi High Court.

However, the Hon'ble Delhi High Court vide its order dated 05 July 2018 has dismissed the Company's petition.

Meanwhile, since the Court has uploaded a copy of the same on its website, the Company is hereby making the disclosure. Also the Company has applied for a certified copy of the order and the same is awaited.

The Company believes it has a strong case and intends to file an appeal against the said order in consultation with its lawyers.

Powered by Capital Market - Live News